124 related articles for article (PubMed ID: 20804099)
1. [Immunohistochemical expression of p53 oncoprotein in Wilms tumour in relation to histological components, histological types and preoperative chemotherapy].
Djuricić S; Djokić D; Vujić D; Basta-Jovanović G; Todorović V; Radojević-Skodrić S; Zdravković S; Vujanić GM
Srp Arh Celok Lek; 2008 Dec; 136 Suppl 4():298-306. PubMed ID: 20804099
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression of p53 proteins in Wilms' tumour: a possible association with the histological prognostic parameter of anaplasia.
Cheah PL; Looi LM; Chan LL
Histopathology; 1996 Jan; 28(1):49-54. PubMed ID: 8838120
[TBL] [Abstract][Full Text] [Related]
3. p53 protein expression in nephroblastomas: a predictor of poor prognosis.
Govender D; Harilal P; Hadley GP; Chetty R
Br J Cancer; 1998; 77(2):314-8. PubMed ID: 9461003
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of nuclear unrest and p53 immunostaining in Wilms' tumor.
Salama A; Kamel A
J Egypt Natl Canc Inst; 2011 Mar; 23(1):31-9. PubMed ID: 22099934
[TBL] [Abstract][Full Text] [Related]
5. p53 expression in Wilms' tumor: a possible role as prognostic factor.
Beniers AJ; Efferth T; Füzesi L; Granzen B; Mertens R; Jakse G
Int J Oncol; 2001 Jan; 18(1):133-9. PubMed ID: 11115550
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of p53 expression in Wilms' tumor in children.
Skotnicka-Klonowicz G; Kobos J; Łoś E; Trejster E; Szymik-Kontorowicz S; Daszkiewicz P
Med Sci Monit; 2001; 7(6):1224-9. PubMed ID: 11687734
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical detection of p53 protein expression as a prognostic factor in Wilms tumor.
Jadali F; Sayadpour D; Rakhshan M; Karimi A; Rouzrokh M; Shamsian BS; Shamshiri AR
Iran J Kidney Dis; 2011 Jul; 5(3):149-53. PubMed ID: 21525573
[TBL] [Abstract][Full Text] [Related]
8. Minichromosome maintenance 2 (MCM2) is a new prognostic proliferative marker in Wilms tumour.
Taran K; Sitkiewicz A; Andrzejewska E; Kobos J
Pol J Pathol; 2011; 62(2):84-8. PubMed ID: 21866463
[TBL] [Abstract][Full Text] [Related]
9. Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity.
Weirich A; Ludwig R; Graf N; Abel U; Leuschner I; Vujanic GM; Mehls O; Boos J; Beck J; Royer-Pokora B; Voûte PA
Ann Oncol; 2004 May; 15(5):808-20. PubMed ID: 15111352
[TBL] [Abstract][Full Text] [Related]
10. SIX1 protein expression selectively identifies blastemal elements in Wilms tumor.
Sehic D; Karlsson J; Sandstedt B; Gisselsson D
Pediatr Blood Cancer; 2012 Jul; 59(1):62-8. PubMed ID: 22180226
[TBL] [Abstract][Full Text] [Related]
11. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.
Reinhard H; Semler O; Bürger D; Bode U; Flentje M; Göbel U; Gutjahr P; Leuschner I; Maass E; Niggli F; Scheel-Walter HG; Stöckle M; Thüroff JW; Tröger J; Weirich A; von Schweinitz D; Zoubek A; Graf N
Klin Padiatr; 2004; 216(3):132-40. PubMed ID: 15175957
[TBL] [Abstract][Full Text] [Related]
12. Multidrug resistance transporter profile reveals MDR3 as a marker for stratification of blastemal Wilms tumour patients.
Hontecillas-Prieto L; Garcia-Dominguez DJ; Vaca DP; Garcia-Mejias R; Marcilla D; Ramirez-Villar GL; Saez C; de Álava E
Oncotarget; 2017 Feb; 8(7):11173-11186. PubMed ID: 28061436
[TBL] [Abstract][Full Text] [Related]
13. p53 Immunohistochemistry expression in Wilms tumor: a prognostic tool in the detection of tumor aggressiveness.
Franken J; Lerut E; Van Poppel H; Bogaert G
J Urol; 2013 Feb; 189(2):664-70. PubMed ID: 23036984
[TBL] [Abstract][Full Text] [Related]
14. The effect of preoperative chemotherapy on histological subtyping and staging of Wilms tumors: The United Kingdom Children's Cancer Study Group (UKCCSG) Wilms tumor trial 3 (UKW3) experience.
Vujanić GM; D'Hooghe E; Popov SD; Sebire NJ; Kelsey A
Pediatr Blood Cancer; 2019 Mar; 66(3):e27549. PubMed ID: 30408319
[TBL] [Abstract][Full Text] [Related]
15. New definitions of focal and diffuse anaplasia in Wilms tumor: the International Society of Paediatric Oncology (SIOP) experience.
Vujanić GM; Harms D; Sandstedt B; Weirich A; de Kraker J; Delemarre JF
Med Pediatr Oncol; 1999 May; 32(5):317-23. PubMed ID: 10219330
[TBL] [Abstract][Full Text] [Related]
16. Blastemal predominant type Wilms tumor in Japan: Japan Children's Cancer Group.
Koshinaga T; Takimoto T; Okita H; Tanaka Y; Inoue E; Oue T; Nozaki M; Tsuchiya K; Haruta M; Kaneko Y; Fukuzawa M
Pediatr Int; 2019 Apr; 61(4):351-357. PubMed ID: 30786111
[TBL] [Abstract][Full Text] [Related]
17. Clinical and biologic significance of nuclear unrest in Wilms tumor.
Hill DA; Shear TD; Liu T; Billups CA; Singh PK; Dome JS
Cancer; 2003 May; 97(9):2318-26. PubMed ID: 12712489
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of cyclin A expression in Wilms tumor.
Radojević-Škodrić S; Brašanac D; Đuričić SM; Glumac S; Lončar Z; Pavlović I; Todorović A; Nikolić G; Baralić I; Pejić S
PeerJ; 2019; 6():e6212. PubMed ID: 30648000
[TBL] [Abstract][Full Text] [Related]
19. Expression of cytokeratin-18-related tissue polypeptide-specific (TPS) antigen in Wilms tumor.
Rebhandl W; Handisurya A; Memaran N; Felberbauer FX; Aberle J; Paya K; Strobl B; Horcher E
Med Pediatr Oncol; 2001 Oct; 37(4):357-64. PubMed ID: 11568899
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of histopathological response to preoperative chemotherapy in unilateral Wilms' tumor: An analysis of 899 patients treated on the SIOP WT 2001 protocol in the UK-CCLG and GPOH studies.
Vujanić GM; D'Hooghe E; Graf N; Vokuhl C; Al-Saadi R; Chowdhury T; Pritchard-Jones K; Furtwängler R
Int J Cancer; 2021 Sep; 149(6):1332-1340. PubMed ID: 34109628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
